Measuring the Rewiring: Connectivity Biomarkers for the Next Generation of Psychiatric Drugs

For pharma teams developing neuroplastogens, from psychedelics to next-generation antidepressants, this piece lays out brain functional connectivity, obtained from EEG or fMRI, as the key biomarker for showing that a drug is reorganizing brain circuits. It covers how Lucerum's standardized qEEG methods turn connectivity into a practical, dose-tracked measure usable across every clinical trial phase, with examples from a real MDD program showing the approach in action, from healthy volunteers through patient outcomes.